BRADLEY SAENGER - 15 Feb 2022 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Financial Officer
Signature
/s/ Bradley Saenger
Issuer symbol
TNXP
Transactions as of
15 Feb 2022
Net transactions value
$0
Form type
4
Filing time
17 Feb 2022, 16:19:03 UTC
Previous filing
11 Feb 2022
Next filing
24 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +900,000 $0.000000 900,000 15 Feb 2022 Common Stock 900,000 $0.2070 Direct F1, F3
transaction TNXP Stock Option Award $0 +900,000 $0.000000 900,000 15 Feb 2022 Common Stock 900,000 $0.4140 Direct F2, F3
transaction TNXP Stock Option Award $0 +900,000 $0.000000 900,000 15 Feb 2022 Common Stock 900,000 $0.6210 Direct F2, F3
transaction TNXP Stock Option Award $0 +900,000 $0.000000 900,000 15 Feb 2022 Common Stock 900,000 $0.8280 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance.
F3 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.